Stories
Slash Boxes
Comments

SoylentNews is people

SoylentNews is powered by your submissions, so send in your scoop. Only 17 submissions in the queue.
posted by janrinok on Tuesday February 18 2020, @06:03PM   Printer-friendly
from the take-one-of-these-and-call-well-umm-maybe-do-not-take-it dept.

New guidelines on aspirin in primary prevention:

In a commentary published online ahead of print in the American Journal of Medicine, researchers from Florida Atlantic University's Schmidt College of Medicine and collaborators from the University of Wisconsin School of Medicine and Public Health, and the Harvard Medical School and Brigham and Women's Hospital, provide guidance to health care providers and their patients. They urge that to do the most good for the most patients in primary care, health care providers should make individual clinical judgements about prescribing aspirin on a case-by-case basis.

"All patients suffering from an acute heart attack should receive 325 mg of regular aspirin promptly, and daily thereafter, to reduce their death rate as well as subsequent risks of heart attacks and strokes," said Charles H. Hennekens, M.D., Dr.P.H., senior author, the first Sir Richard Doll Professor, and senior academic advisor in FAU's Schmidt College of Medicine. "In addition, among long-term survivors of prior heart attacks or occlusive strokes, aspirin should be prescribed long-term unless there is a specific contraindication. In primary prevention, however, the balance of absolute benefits, which are lower than in secondary prevention patients, and risks of aspirin, which are the same as in secondary prevention, is far less clear."

The researchers emphasize that, based on the current totality of evidence, any judgments about prescribing long-term aspirin therapy for apparently healthy individuals should be based on individual clinical judgments between the health care provider and each of his or her patients that weighs the absolute benefit on clotting against the absolute risk of bleeding.

[...] "General guidelines for aspirin in primary prevention do not seem to be justified," said Hennekens. "As is generally the case, the primary care provider has the most complete information about the benefits and risks for each of his or her patients."

Journal Reference:

Alexander Gitin, Marc A Pfeffer, David L. DeMets, Charles H. Hennekens. ASPIRIN IN PRIMARY PREVENTION: NEEDS INDIVIDUAL JUDGMENTS. The American Journal of Medicine, 2020; DOI: 10.1016/j.amjmed.2020.01.006


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 1, Informative) by Anonymous Coward on Wednesday February 19 2020, @08:41AM

    by Anonymous Coward on Wednesday February 19 2020, @08:41AM (#959824)

    Bayer has no aspirin trademark [wikipedia.org] in the U.S. like it does in Canada. I am holding a bottle of generic Safeway aspirin right now.

    Starting Score:    0  points
    Moderation   +1  
       Informative=1, Total=1
    Extra 'Informative' Modifier   0  

    Total Score:   1